The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clonal tumor evolution under induction chemotherapy and concurrent radiochemotherapy (RCHT) in patients with resectable stage IIIA (N2) and selected IIIb non-small cell lung cancer (NSCLC): Molecular analysis of the ESPATUE randomized phase III trial.
 
Sayedmohammad Hasheminasab
No Relationships to Disclose
 
Maximilian Knoll
No Relationships to Disclose
 
Christian Schwager
No Relationships to Disclose
 
Ali Nowrouzi
No Relationships to Disclose
 
Nicole Pfarr
No Relationships to Disclose
 
Wilko Weichert
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Research Funding - Bristol-Myers Squibb (Inst); Bruker (Inst); Merck Sharp & Dohme (Inst); Roche (Inst)
 
Stefan Rieken
No Relationships to Disclose
 
Christoph Pöttgen
Honoraria - AstraZeneca; Boehringer Ingelheim; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Roche Pharma AG
Travel, Accommodations, Expenses - Boehringer Ingelheim; Roche Pharma AG
 
Thomas Christoph Gauler
No Relationships to Disclose
 
Wilfried Eberhardt
No Relationships to Disclose
 
Martin H. Schuler
Honoraria - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; MSD; Novartis; Pierre Fabre
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Novartis; Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Highly sensitive method for mutation detection by PCR (Inst)
 
Dirk Theegarten
No Relationships to Disclose
 
Clemens Aigner
No Relationships to Disclose
 
Juergen Debus
Research Funding - Accuray (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Ergomed (Inst); Merck Serono (Inst); Nanobiotix (Inst); Pharmaceutical Research Associates (Inst); PTW (Inst); Quintiles (Inst); RaySearch Laboratories (Inst); Siemens (Inst); Solution Akademie GmbH (Inst); The Clinical Research Institute Gmbh (Inst); ViewRay (Inst); Vision RT (Inst)
 
Martin Stuschke
No Relationships to Disclose
 
Amir Abdollahi
Consulting or Advisory Role - Bayer Health (Inst); BMS Brazil (Inst); FibroGen (Inst); Merck KGaA (Inst); Merck Serono (Inst); Roche (Inst); Varian Medical Systems (Inst)
Research Funding - Bayer (Inst); FibroGen (Inst); Merck KGaA (Inst)